🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

RecruitingPhase 2Ages 18 Years - 80 YearsAllUniversity Hospital, Toulouse
NCT07488117 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18-80 years; * meeting clinical criteria for "possible" AE with identified antibodies; * newly diagnosed with symptoms \<6 months; * no second-line immunosuppressive treatment; * high or mixed TSPO binding affinity phenotype. Exclusion Criteria: * Pregnant women; * contraindications to MRI; * known allergic reaction to \[18F\]-DPA-714; legal protection measure; * paraneoplastic syndrome following immune checkpoint inhibitor therapy.
💊

What it tests

  • TEP with radioligand EAI 714
📍

Where

1 site
University Hospital
Toulouse, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy